You’re ignoring the reality. For instance EAMS was the PIM designation and they have been providing early access in the UK for years now. The facility in London and now Sawston will expand their capacity for EAMS. Which is early access.
The HE situation was new. Turned out the Germans snuck some protectionist provisions in it. It was given. It was awarded. So they went for it and got it. But early access under the HE in Germany required local manufacturing and that would be a diversion of resources and a waste when they needed them to keep focused.
On the prostrate trial, had a partner stepped forward to find it, or had their share price risen commensurate with the potential of DCVax, possibly they could have funded it, but they chose to limit their expenses and concentrate on DCVax-L, which is a significant partnership effectively with UCLA and burnishes all of their efforts with a whole additional level of impressiveness.
So I would look at the situation differently than you just painted it, which is a notion that they never finish anything, which again, if one believes in the science and remains invested for that reason, is a strange argument to make.
As for the change that became apparent on the announcement of results, it may have come only once they started discussing with what is ultimately a large number of advisors which was in that list originally. Their process. They had to reemphasize it. It is it just up to management to say what was the wisest course and they got advice to do it another way, is my guess, and of course it would come after they had it and had coordinated with all of their advisors. You make it sound like that is some sort of crime.
And there is no such thing as Buzdargate. Buzdar had nothing to do with this trial. He was never connected to it. He was just some random doctor that AdamFuerstrin got to make an unflattering comment, and who later violated his own statemsnts on this trial with statements in his own trial. That there are such people in research and the medical medical world that can almost be rented and rolled out to be used as a means to sabotage someone else’s trial, and help manufacture a controversy, is a reality. I have seen it multiple times with cell therapies. We do not know what his true motives were given that he broke his own supposed rules subsequently, he seems to have not been entirely sincere though certainly, momentarily he created some MINOR controversy that has no impact in reality. It does not affect the science, it does not affect any of the regulatory authorities, it did not cause any consequential legal claims. Nada. It had NO impact. Therefore it was not the equivalent of a “watergate”. It was a tempest in a teapot, ultimately.
Some can keep harping on these inconsequential loud noises and false light controversies. Note that Adam focused on the German laws failure, but made it seem like it was NWBO’s fault when basically that law was announced by the Germans with great fanfare and has produced very little for Germans in any context. It was not NWBO’s fault that they took the German regulator seriously on what seemed like an opportunity and did everything they were supposed to do to qualify DCVax-L other than move their manufacturing to Germany. You and AF make that sound like they committed a crime by successfully jumping through those German hoops. And who knows, there may still be some future regulatory benefit from that designation at the time of their application for full approval. They had to do a lot of work to get that certification.
No, it is nothing like the never ending darkness you just painted in that post. This is what it is like when you invest in a microcap bio that has been under resourced and attacked non-stop by rivals.
News 
Market Data 
Discover 
